The recently announced divestment of Animal Nutrition & Health marks the final step in executing the strategic roadmap to becoming a leading consumer-focused company in nutrition, health, and beauty, enabling the company to fully focus on core strengths and deliver sustainable long-term value for stakeholders. Focus on health-driven innovations, sustainability, and bio-based solutions enhances product differentiation and pricing power, with integration synergies boosting margin improvements and revenue stability.
Cyborg Score Rationale
Analysts have made major negative revisions to near-term forecasts, with both revenue and earnings per share forecasts declining significantly, suggesting analysts have soured majorly on the business. While revenue growth is expected to slow to 2.7% annualized growth through 2026 versus historical 12% p.a., growth is expected to be roughly in line with the industry. Strategic portfolio optimization through ANH divestiture provides near-term execution risk but medium-term margin upside.
Top Insights
February 2026: DSM-Firmenich divests Animal Nutrition & Health business to CVC Capital Partners for €2.2 billion enterprise value while retaining a 20% equity stake.
Completed €1.08 billion share repurchase program ahead of schedule, buying back nearly 13 million shares with plans to cancel over 12 million shares in early 2026.
Analysts forecast 2026 revenues of €9.3 billion reflecting 2.7% growth versus 12% historical growth rates.
Operates through four segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health.
Named Competitors
IFF — Leading global flavor and fragrance producer
Givaudan — Premium fragrance and flavor company
Symrise — Specialty chemicals and fragrance provider
Dupont — Nutrition and biosciences competitor
Recent Developments
(February 2026) Full year 2025 results released with €1.9 billion impairment for ANH divestiture
(February 2026) Animal Nutrition & Health divestiture to CVC Capital Partners announced for €2.2 billion
(February 2026) €1.08 billion share buyback program completed ahead of schedule
(January 2026) €500 million new share repurchase program announced for 2026
Open the full interactive DSM-Firmenich AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.